Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2007 by Cooperative Study Group A for Hematology.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Cooperative Study Group A for Hematology
ClinicalTrials.gov Identifier:
NCT00561301
First received: November 18, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

November 18, 2007
November 18, 2007
November 2006
Not Provided
objective response rate [ Time Frame: 10/2009 ]
Same as current
No Changes Posted
toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT [ Time Frame: 10/2009 ]
Same as current
Not Provided
Not Provided
 
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma
Drug: GemDOx
gemcitabine oxliplatin
No Intervention: 1
Intervention: Drug: GemDOx
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
43
October 2009
Not Provided

Inclusion Criteria:

  • Patients who have refractory to first-line CHOP-like regimen
  • Patients who have first relapse after
  • first-line CHOP-like regimen
  • upfront autologous or allogeneic hematopoietic stem cell transplantation
  • Age 15 years or more
  • ECOG performance status ≤ 2
  • Adequate bone marrow function
  • Adequate kidney,liver,cardiac

Exclusion Criteria:

  • Patients who have received GEM or OX
Both
15 Years to 65 Years
No
Contact: Yae Eun Jang 82-2-3010-7290 redpin75@paran.com
Korea, Republic of
 
NCT00561301
C-012A
No
Not Provided
Cooperative Study Group A for Hematology
Not Provided
Principal Investigator: Hawk Kim, professor Ulsan Universtity Hospital, ROK
Cooperative Study Group A for Hematology
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP